BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29512767)

  • 1. Knockdown of ZEB1 suppressed the formation of vasculogenic mimicry and epithelial-mesenchymal transition in the human breast cancer cell line MDA-MB-231.
    Liang W; Song S; Xu Y; Li H; Liu H
    Mol Med Rep; 2018 May; 17(5):6711-6716. PubMed ID: 29512767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 knockdown suppresses vasculogenic mimicry of non-small cell lung cancer by modulating ZEB1-triggered EMT.
    Li W; Wu J; Jia Q; Shi Y; Li F; Zhang L; Shi F; Wang X; Wu S
    BMC Cancer; 2024 May; 24(1):633. PubMed ID: 38783271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition.
    Liu Z; Sun B; Qi L; Li H; Gao J; Leng X
    Cancer Sci; 2012 Apr; 103(4):813-20. PubMed ID: 22212097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
    Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells.
    Langer EM; Kendsersky ND; Daniel CJ; Kuziel GM; Pelz C; Murphy KM; Capecchi MR; Sears RC
    Oncogene; 2018 Feb; 37(8):1005-1019. PubMed ID: 29084210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deubiquitinase BRCC3 increases the stability of ZEB1 and promotes the proliferation and metastasis of triple-negative breast cancer cells.
    Huang Q; Zheng S; Gu H; Yang Z; Lu Y; Yu X; Guo G
    Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):564-575. PubMed ID: 38449391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study on inhibition of Britannin on triple-negative breast carcinoma through degrading ZEB1 proteins.
    Lu H; Wu Z; Wang Y; Zhao D; Zhang B; Hong M
    Phytomedicine; 2022 Sep; 104():154291. PubMed ID: 35839735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
    Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
    Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA 34a-AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells.
    Lim D; Cho JG; Yun E; Lee A; Ryu HY; Lee YJ; Yoon S; Chang W; Lee MS; Kwon BS; Kim J
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation exposure triggers the progression of triple negative breast cancer via stabilizing ZEB1.
    Lin Y; Bai X; Zhou W; He Y; Wu Y; Wang X
    Biomed Pharmacother; 2018 Nov; 107():1624-1630. PubMed ID: 30257380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of miR‑93 on epithelial‑to‑mesenchymal transition and vasculogenic mimicry in triple‑negative breast cancer cells.
    An G; Lu F; Huang S; Bai J; He L; Liu Y; Hou L
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
    Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
    [No Abstract]   [Full Text] [Related]  

  • 13. miR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor ZEB1/2.
    Ma P; Ni K; Ke J; Zhang W; Feng Y; Mao Q
    Exp Biol Med (Maywood); 2018 Mar; 243(5):473-480. PubMed ID: 29368542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brucine Suppresses Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cell Line MDA-MB-231.
    Xu MR; Wei PF; Suo MZ; Hu Y; Ding W; Su L; Zhu YD; Song WJ; Tang GH; Zhang M; Li P
    Biomed Res Int; 2019; 2019():6543230. PubMed ID: 30723742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsa-miR-497-3p impedes the proliferation and invasion of triple-negative breast cancer cells by controlling epithelial-mesenchymal transition through ZEB1 targeting.
    Dong Q; Chen H; Li Y; Kong Y; Geng C; Liu Y
    Cell Mol Biol (Noisy-le-grand); 2023 Aug; 69(8):78-83. PubMed ID: 37715420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZEB2 promotes vasculogenic mimicry by TGF-β1 induced epithelial-to-mesenchymal transition in hepatocellular carcinoma.
    Yang Z; Sun B; Li Y; Zhao X; Zhao X; Gu Q; An J; Dong X; Liu F; Wang Y
    Exp Mol Pathol; 2015 Jun; 98(3):352-9. PubMed ID: 25818166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT3 Targets
    Ma JH; Qi J; Lin SQ; Zhang CY; Liu FY; Xie WD; Li X
    Mol Cancer Res; 2019 Nov; 17(11):2184-2195. PubMed ID: 31427441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Expression and Functional Significance of Runx2 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry and Epithelial-Mesenchymal Transition.
    Cao Z; Sun B; Zhao X; Zhang Y; Gu Q; Liang X; Dong X; Zhao N
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells.
    Maroufi NF; Amiri M; Dizaji BF; Vahedian V; Akbarzadeh M; Roshanravan N; Haiaty S; Nouri M; Rashidi MR
    Eur J Pharmacol; 2020 Aug; 881():173282. PubMed ID: 32580038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
    Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
    Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.